Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025

Reuters

10/20

Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025

Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate $(ADC)$, in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01587) on October 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576000644"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576000644\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576000644?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576000644","market":"nz","top_or_hot":-1,"title":"Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01587) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 09:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01587) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06996","symbol_name":"德琪医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL8yfGk1:1","article_id":"2576000644","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576000644","pubTimestamp":1760922025,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate , in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025  in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06996":"德琪医药-B","BK1574":"生物医药B类股","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"德琪医药在ESMO 2025上报告ATG-022治疗胃癌的I/II期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":0.9},"content_text":"Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025\n    \n\n        Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate $(ADC)$, in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01587) on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}